Chemoinformaics analysis of (+)-epi-erythratidine
| Molecular Weight | 331.412 | nRot | 3 |
| Heavy Atom Molecular Weight | 306.212 | nRig | 20 |
| Exact Molecular Weight | 331.178 | nRing | 4 |
| Solubility: LogS | -2.143 | nHRing | 2 |
| Solubility: LogP | 1.648 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 49 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 25 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 6 |
| nHA | 5 | APOL | 52.7078 |
| nHD | 1 | BPOL | 31.9982 |
| QED | 0.857 |
| Synth | 4.421 |
| Natural Product Likeliness | 2.156 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.581 |
| Pgp-sub | 0.915 |
| HIA | 0.013 |
| CACO-2 | -4.588 |
| MDCK | 0.0000139 |
| BBB | 0.973 |
| PPB | 0.540012 |
| VDSS | 2.011 |
| FU | 0.372147 |
| CYP1A2-inh | 0.017 |
| CYP1A2-sub | 0.66 |
| CYP2c19-inh | 0.026 |
| CYP2c19-sub | 0.96 |
| CYP2c9-inh | 0.016 |
| CYP2c9-sub | 0.415 |
| CYP2d6-inh | 0.033 |
| CYP2d6-sub | 0.844 |
| CYP3a4-inh | 0.046 |
| CYP3a4-sub | 0.93 |
| CL | 10.219 |
| T12 | 0.559 |
| hERG | 0.03 |
| Ames | 0.54 |
| ROA | 0.49 |
| SkinSen | 0.018 |
| Carcinogencity | 0.529 |
| EI | 0.008 |
| Respiratory | 0.95 |
| NR-Aromatase | 0.229 |
| Antiviral | No |
| Prediction | 0.587986 |